How to buy Athenex stock | 13.05

Athenex, Inc is a drug manufacturers—specialty & generic business based in the US. Athenex shares (ATNX) are listed on the NASDAQ and all prices are listed in US Dollars. Athenex employs 574 staff and has a trailing 12-month revenue of around USD$140.8 million.

How to buy shares in Athenex

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Athenex. Find the stock by name or ticker symbol: ATNX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Athenex reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$13.05, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Athenex, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Athenex. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Athenex's share price?

Since the stock market crash in March caused by coronavirus, Athenex's share price has had significant negative movement.

Its last market close was USD$13.05, which is 6.72% down on its pre-crash value of USD$13.99 and 131.79% up on the lowest point reached during the March crash when the shares fell as low as USD$5.63.

If you had bought USD$1,000 worth of Athenex shares at the start of February 2020, those shares would have been worth USD$486.63 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$942.21.

Athenex share price

Use our graph to track the performance of ATNX stocks over time.

Athenex shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$13.05
52-week range	USD$5.63 - USD$18.35
50-day moving average	USD$12.6054
200-day moving average	USD$11.4558
Wall St. target price	USD$28.24
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.055

Buy Athenex shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Athenex stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Athenex, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Athenex price performance over time

Historical closes compared with the close of $13.05 from 2020-11-16

1 week (2020-11-23)	-6.79%
1 month (2020-10-30)	14.47%
3 months (2020-08-28)	21.85%
6 months (2020-05-29)	20.06%

1 year (2019-11-29)	-16.24%
2 years (2018-11-30)	-1.29%
3 years (2017-11-30)	-23.73%
5 years (2015-11-27)	N/A

Athenex financials

Revenue TTM	USD$140.8 million
Gross profit TTM	USD$-49,362,000
Return on assets TTM	-20.67%
Return on equity TTM	-80.4%
Profit margin	-82.63%
Book value	$1.705
Market capitalisation	USD$1.1 billion

TTM: trailing 12 months

Shorting Athenex shares

There are currently 9.7 million Athenex shares held short by investors – that's known as Athenex's "short interest". This figure is 7.7% up from 9.0 million last month.

There are a few different ways that this level of interest in shorting Athenex shares can be evaluated.

Athenex's "short interest ratio" (SIR)

Athenex's "short interest ratio" (SIR) is the quantity of Athenex shares currently shorted divided by the average quantity of Athenex shares traded daily (recently around 1.5 million). Athenex's SIR currently stands at 6.32. In other words for every 100,000 Athenex shares traded daily on the market, roughly 6320 shares are currently held short.

However Athenex's short interest can also be evaluated against the total number of Athenex shares, or, against the total number of tradable Athenex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Athenex's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Athenex shares in existence, roughly 110 shares are currently held short) or 0.1361% of the tradable shares (for every 100,000 tradable Athenex shares, roughly 136 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Athenex.

Find out more about how you can short Athenex stock.

Athenex share dividends

We're not expecting Athenex to pay a dividend over the next 12 months.

Athenex share price volatility

Over the last 12 months, Athenex's shares have ranged in value from as little as $5.63 up to $18.35. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athenex's is 0.856. This would suggest that Athenex's shares are less volatile than average (for this exchange).

Athenex overview

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

Frequently asked questions

• What percentage of Athenex is owned by insiders or institutions?

  Currently 18.37% of Athenex shares are held by insiders and 54.28% by institutions.

• How many people work for Athenex?

  Latest data suggests 574 work at Athenex.

• When does the fiscal year end for Athenex?

  Athenex's fiscal year ends in December.

• Where is Athenex based?

  Athenex's address is: Conventus Building, Buffalo, NY, United States, 14203

• What is Athenex's ISIN number?

  Athenex's international securities identification number is: US04685N1037

• What is Athenex's CUSIP number?

  Athenex's Committee on Uniform Securities Identification Procedures number is: 04685N103